BioSpace News Archive

Cerapedics, a privately-held orthobiologics company, today announced results from the IVANOS study evaluating i-FACTOR™ Peptide Enhanced Bone Graft in lumbar posterolateral spine surgery.

The Indiana Biosciences Research Institute (IBRI) today announced the appointment of Mark E. Craft as executive director of engagement, communications and external affairs.

Amgen(NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab).

Surrozen, a preclinical-stage company advancing drug candidates that promote the repair and regeneration of human tissues, today announced two appointments to expand its leadership team. Craig Parker, a biotech industry veteran recently of Jazz Pharmaceuticals, has been appointed CEO, and Hans Clevers, M.D., Ph.D., professor of molecular genetics at the Hubrecht Institute, has been appointed scientific co-founder of Surrozen.

The coreHEM initiative has announced the publication of a core outcome set for clinical trials of gene therapy in hemophilia.

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure.

May 21, 2018 18:15 UTC Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients Sesen Bio (Formally Eleven Biotherapeutics) Reports Positive, Three-Month Data from VISTA Trial of Vicinium™ in High-Grade NMIBC Data Presented During Plenary Session at American Urological Association Annual Meeting Company to Host Co

Cutting-edge technologies and equipment found at Asia Agri-Tech Expo from July 26-28

UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercialising antibiotics in the US, today announced that the U.S. Food and Drug Administration (FDA) has designated both mecillinam (injectable) and pivmecillinam (oral prodrug) as Qualified Infectious Disease Products (QIDP) for the indication of complicated urinary tract infections (cUTI).

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced positive topline results after data base lock in the phase I single ascending dose (SAD) clinical study of KL1333, a novel treatment in clinical development for orphan genetic mitochondrial diseases.